Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Cancer Causes & Control, an esteemed journal within the field of Cancer Research and Oncology, is published by SPRINGER. Since its inception in 1990, this journal has dedicated itself to exploring the complex interplay between environmental, genetic, and lifestyle factors that contribute to cancer causation and control, aiming to inform public health initiatives and improve cancer prevention strategies. With an impressive Q2 rank in both its categories, the journal serves as a vital resource for researchers, professionals, and students seeking insights into the latest findings and methodologies in cancer epidemiology. Although there is no Open Access option, researchers can access valuable articles that reflect rigorous peer review and significant contributions to the field. The journal’s commitment to advancing knowledge related to cancer risks and management makes it an essential platform for disseminating impactful research and fostering collaboration among scholars worldwide.

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.

Cancer Epidemiology Biomarkers & Prevention is a premier journal published by the American Association for Cancer Research, dedicated to advancing the understanding of cancer epidemiology, biomarkers, and preventive strategies. With an impressive impact factor that places it in the Q1 quartile across three critical categories — Epidemiology, Medicine, and Oncology — the journal stands as a vital resource for researchers and healthcare professionals seeking to explore novel insights in cancer prevention and control. The journal's rigorous selection process ensures the high quality of published research, making it a trusted source for the latest findings and methodologies in the fight against cancer. Although it currently does not support open access, the journal's comprehensive articles, spanning from its inception in 1983 to the present, facilitate significant advancements in the field. Located in Philadelphia, PA, this journal not only serves as a platform for dissemination but also stimulates vital discussions among the oncology community, ensuring that significant translational research reaches its audience effectively.

CA: A Cancer Journal for Clinicians is a prestigious academic journal published by Wiley, serving as a leading source of evidence-based information for those in the fields of oncology and hematology. With an impressive impact factor and ranked in the top quartile (Q1) for both specialties, this journal aims to bridge the gap between the latest research findings and clinical practice. Established in 1950, it boasts a long-standing history of delivering essential insights, guidelines, and innovative strategies to healthcare professionals worldwide, making significant contributions to the understanding and treatment of cancer. Although it does not offer open access, its published content is crucial for researchers, clinicians, and students dedicated to advancing cancer care. The journal's commitment to excellence is reflected in its elite rankings, holding the #1 position in both the Medicine – Oncology and Medicine – Hematology categories according to Scopus, positioning it in the 99th percentile of scholarly impact.

Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

Hereditary Cancer in Clinical Practice, published by BMC in the United Kingdom, is a prominent open access journal dedicated to advancing knowledge in the realms of clinical genetics and oncology. Established in 2003, the journal has positioned itself as a vital resource for researchers, clinicians, and students interested in the genetic underpinnings of cancer and its implications for patient care. With a Q3 ranking in Genetics (Clinical) and a Q2 ranking in Oncology for 2023, the journal emphasizes high-quality, peer-reviewed articles that foster dialogue and innovation in hereditary cancer research. Furthermore, its commitment to open access ensures that the latest findings and methodologies are readily available to the global academic community, reflecting a broader trend toward accessibility in scientific literature. From 2004 to 2024, it aims to host a diverse array of studies, reviews, and clinical reports that are integral to understanding the complexities of hereditary cancer, making it an essential platform for those dedicated to unraveling these intricate challenges.

Cancer Prevention Research, published by the American Association for Cancer Research, is a leading journal dedicated to advancing our understanding of cancer prevention strategies and their implementation in public health. With an ISSN of 1940-6207 and E-ISSN 1940-6215, this journal serves as a pivotal platform for researchers, healthcare professionals, and students who are committed to unraveling the complexities of cancer etiology and preventive measures. Since its inception in 2008, the journal has carved a niche in the scientific community, achieving notable rankings including Q2 in Cancer Research and Q1 in both Medicine (miscellaneous) and Oncology, highlighting its significance in disseminating influential research. Cancer Prevention Research is indexed in Scopus, reflecting a robust impact factor, and features a range of articles that address the preventive aspects of cancer to promote healthier populations. With access options available, it invites contributions that bridge laboratory findings with epidemiologic insights, making it an essential resource for anyone dedicated to reducing the burden of cancer globally.

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.